| 858 |
Carboplatin
|
-
Carboplatin, CAS-RN: 41575-94-4, DTXSID3046742
|
472: DNA adduct formation leading to kidney failure
|
| 857 |
Oxaliplatin
|
-
Oxaliplatin, CAS-RN: 61825-94-3, DTXSID0036760
|
472: DNA adduct formation leading to kidney failure
|
| 856 |
Chlorotoluron
|
-
Chlorotoluron, CAS-RN: 15545-48-9, DTXSID8052853
|
567: Binding to plastoquinone B site leading to decreased population growth rate via photosystem II inhibition
|
| 855 |
Metribuzin
|
-
Metribuzin, CAS-RN: 21087-64-9, DTXSID6024204
|
567: Binding to plastoquinone B site leading to decreased population growth rate via photosystem II inhibition
|
| 854 |
ML385
|
|
615: Suppression of Keap1 cysteine oxidation leading to liver inflammation
|
| 853 |
Brusatol
|
|
615: Suppression of Keap1 cysteine oxidation leading to liver inflammation
|
| 852 |
Tebufenpyrad
|
-
Tebufenpyrad, CAS-RN: 119168-77-3, DTXSID0034223
|
3: Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits
|
| 851 |
Pyrimidifen
|
-
Pyrimidifen, CAS-RN: 105779-78-0, DTXSID9057925
|
3: Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits
|
| 850 |
Deguelin
|
-
Deguelin, CAS-RN: 522-17-8, DTXSID10200231
|
3: Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits
|
| 849 |
Cucurbitacin D
|
|
606: Ecdysone receptor antagonism leading to mortality via inhibition of chitin synthase 1
|
| 848 |
Cucurbitacin B
|
|
606: Ecdysone receptor antagonism leading to mortality via inhibition of chitin synthase 1
|
| 847 |
Muristerone A
|
|
342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
|
| 846 |
Picoxystrobin
|
-
Picoxystrobin, CAS-RN: 117428-22-5, DTXSID9047542
|
587: Inhibition of the mitochondrial complex III of nigro-striatal neurons leads to parkinsonian motor deficits
|
| 845 |
2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether
|
-
2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether, CAS-RN: 1163-19-5, DTXSID9020376
|
None
|
| 844 |
Wilson's disease
|
|
590: Increase of intracellular copper leading to cuproptosis via interference with energy metabolism
|
| 843 |
Elesclomol
|
|
590: Increase of intracellular copper leading to cuproptosis via interference with energy metabolism
|
| 842 |
CuO nanoparticles
|
|
590: Increase of intracellular copper leading to cuproptosis via interference with energy metabolism
|
| 841 |
calcium ionophore
|
|
None
|
| 840 |
Redox status
|
|
504: SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level
|
| 839 |
Tissue transglutaminase 2 (TG2) enzyme activity
|
|
524: Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals
|
| 838 |
Bacterial or viral Infections
|
|
524: Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals
|
| 837 |
Gluten
|
|
524: Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals
|
| 836 |
7,12-Dimethylbenz(a)anthracene
|
-
7,12-Dimethylbenz(a)anthracene, CAS-RN: 57-97-6, DTXSID1020510
|
563: Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis
|
| 835 |
3,3',5,5'-Tetrabromobisphenol A
|
-
3,3',5,5'-Tetrabromobisphenol A, CAS-RN: 79-94-7, DTXSID1026081
|
565: 17β-Hydroxysteroid dehydrogenase 2, inhibition leading to activation, estrogen receptor alpha
|
| 834 |
1,1'-Ethane-1,2-diylbis(pentabromobenzene)
|
-
1,1'-Ethane-1,2-diylbis(pentabromobenzene), CAS-RN: 84852-53-9, DTXSID2052732
|
3 AOPs
|